Innate Pharma highlights next generation of cancer immunotherapies
at the American Association of Cancer Research (AACR) 2019 annual
meeting
INNATE PHARMA HIGHLIGHTS NEXT GENERATION
OF CANCER IMMUNOTHERAPIES AT THE AMERICAN ASSOCIATION OF CANCER
RESEARCH (AACR) 2019 ANNUAL MEETING
- New preclinical data highlights IPH5201 (anti-CD39) and
IHP5301 (anti-CD73) neutralizing antibodies targeting the
immunosuppressive adenosine pathway
- First data presented from Innate Pharma’s proprietary
multi-specific NK-cell engager (NKCE) technology for fighting
cancers
- Conference session chaired by Chief Scientific Officer
Eric Vivier at AACR 2019
Marseille,
France, April 1, 2019, 07:00 AM CET
Innate Pharma SA (the “Company” - Euronext
Paris: FR0010331421 – IPH) today announced that new preclinical
data from the Company’s innovative portfolio of next generation
immunotherapies has been presented in a conference session by Pr.
Eric Vivier, Chief Scientific Officer, at the American Association
for Cancer Research (AACR) Annual Meeting held from March 29–April
3, in Atlanta.
Eric Vivier, Chief Scientific Officer of
Innate Pharma, said: “Innate Pharma has always been driven
by scientific leadership and we are very proud to present new
preclinical data from our broad and innovative portfolio of next
generation cancer immunotherapies. For the first time, we also
shared data from our multi-specific NK-cell engager technology that
highlight a new generation of molecules for fighting
cancers.”
While chairing the conference session “Innate
Immunity and Complement in Solid Tumors”, the following findings
were presented by Eric Vivier in a lecture titled “Targeting innate
immunity in next generation cancer immunotherapies” yesterday at
AACR:
IPH5201 (anti-CD39) and IPH5301
(anti-CD73), targeting the adenosine pathway:
CD39 and CD73 are membrane-bound extracellular
enzymes which play a major role in promoting immunosuppression
through the pathway degrading adenosine triphosphate (ATP) into
immunosuppressive adenosine (Ado). The blockade of CD39 and CD73
has the potential to promote anti-tumor immune responses across a
wide range of tumors.
New data demonstrate that a combination of
Innate Pharma’s anti-CD39 monoclonal antibody, IPH5201, and
ATP-inducing oxaliplatin had a synergistic effect that improved the
control of tumor growth in a preclinical mouse model.
Previous findings showed that IPH5201 enhances
the stimulatory effect of ATP on antigen presenting cells and
abrogates the suppressive effect of ATP-derived Ado on the
proliferation of T cells from healthy donors and cancer patients.
In October 2018, Innate Pharma and AstraZeneca entered into a
development collaboration and option for further co-development and
co-commercialization for IPH5201.
New data from a crystal structure of the
CD73/IPH5301 complex support a model for the differentiated mode of
action of IPH5301 and enhanced efficacy compared to competitors.
Analysis by electron microscopy revealed that the IPH5301
monoclonal antibody interacts mainly with CD73 dimer in an
intra-dimer mode, constraining the CD73 enzyme in an inactive state
in which AMP could not be hydrolyzed, in contrast to other
antibodies in development that interact in an inter-dimer mode.
Findings presented at the 2018 American Association of Cancer
Research (AACR) conference demonstrated that IPH5301 is more potent
in vitro than benchmark anti-CD73 antibodies currently under
clinical development, on both membrane-bound and soluble CD73, in
enzymatic activity as well as T cell proliferation assays.
Innate expects INDs to be filed for IPH5201 in
the second half of 2019 and for IPH5301 in the first half of
2020.
First-in-class trifunctional NKCEs
create a new generation of molecules for fighting
cancer:
Innate Pharma’s proprietary multifunctional NKCE
technology targets two activating receptors, NKp46 and CD16, on NK
cells and a tumor antigen on cancer cells.
New pre-clinical data outlined in the
presentation demonstrate that these first-in-class trifunctional
NKCEs are more potent in vitro and in vivo than clinical
therapeutic monoclonal antibodies targeting the same tumor antigen,
such as rituximab, obinituzumab or cetuximab, with no off-target
effects. The data also demonstrate that co-engagement of NKp46
synergizes with CD16 to potentiate both tumor cell lysis and NK
cell activation.
NKCEs stimulate NK cells instead of T cells and
have been designed to improve the benefit-risk profile for the
treatment of solid tumors.
Innate Pharma has a research collaboration and
licensing agreement with Sanofi for the generation and evaluation
of up to two multifunctional NK cell engagers, using both Innate
Pharma’s and Sanofi’s technology and tumor targets. Under the terms
of the license agreement, Sanofi is responsible for the
development, manufacturing and commercialization of products
resulting from the research collaboration. Innate Pharma is
eligible for up to €400m in development and commercial milestone
payments as well as royalties on net sales.
The presentation is available on Innate Pharma’s
website.
About Innate Pharma:Innate
Pharma S.A. is a fully integrated oncology-focused biotech company
dedicated to improving treatment and clinical outcomes for patients
through therapeutic antibodies that harness the immune system to
fight cancer.
Innate Pharma’s commercial-stage product,
Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in
September 2018. Lumoxiti is a first-in class specialty oncology
product for hairy cell leukemia (HCL). Innate Pharma’s broad
pipeline of antibodies includes several first-in-class clinical and
preclinical candidates in cancers with high unmet medical need.
Innate Pharma has pioneered the discovery and
development of checkpoint inhibitors, with a unique expertise and
understanding of Natural Killer cell biology. This innovative
approach has resulted in major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a landmark and multi-products partnership
with AstraZeneca.
Based in Marseille, France, Innate Pharma is listed
on Euronext Paris.
Learn more about Innate Pharma at
www.innate-pharma.com
Information about Innate Pharma
shares:
ISIN codeTicker
codeLEI |
FR0010331421IPH9695002Y8420ZB8HJE29 |
Disclaimer:
This press release contains certain
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. For a discussion of risks and
uncertainties which could cause the company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors (“Facteurs de Risque") section of the Document de
Reference prospectus filed with the AMF, which is available on the
AMF website (http://www.amf-france.org) or on Innate Pharma’s
website.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
Investors Innate
Pharma Dr Markus Metzger / Danielle Spangler /
Jérôme MarinoInvestor relations Tel.: +33 (0)4 30 30 30 30
investors@innate-pharma.com |
International Media
Consilium Strategic Communications Mary-Jane
Elliott / Jessica Hodgson / Melissa Gardiner Tel.: +44 (0)20 3709
5700 InnatePharma@consilium-comms.com |
|
French Media ATCG
Press Solène Moulin Tel.: +33 (0)9 81 87 46 72
presse@atcg-partners.com |
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024